# A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma

> **NCT03339219** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 35 (actual)

## Conditions studied

- Advanced Renal Cell Carcinoma

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT03339219
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-13
- **Primary completion:** 2020-08-25
- **Final completion:** 2020-08-25
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2021-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03339219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03339219, "A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03339219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*